These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32109375)

  • 1. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
    Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
    Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
    Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer.
    Knudsen ES; Kumarasamy V; Ruiz A; Sivinski J; Chung S; Grant A; Vail P; Chauhan SS; Jie T; Riall TS; Witkiewicz AK
    Oncogene; 2019 May; 38(18):3355-3370. PubMed ID: 30696953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
    Franco J; Witkiewicz AK; Knudsen ES
    Oncotarget; 2014 Aug; 5(15):6512-25. PubMed ID: 25156567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
    Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
    Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
    Kumarasamy V; Ruiz A; Nambiar R; Witkiewicz AK; Knudsen ES
    Oncogene; 2020 Feb; 39(9):1831-1845. PubMed ID: 31745297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
    Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
    Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
    Zhang B; Li D; Jin X; Zhang K
    Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.
    Ji Y; Liu X; Li J; Xie X; Huang M; Jiang J; Liao YP; Donahue T; Meng H
    Nat Commun; 2020 Aug; 11(1):4249. PubMed ID: 32843618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
    Tang H; Ge Y; You T; Li X; Wang Y; Cheng Y; Bai C
    BMC Cancer; 2023 Oct; 23(1):958. PubMed ID: 37817078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.